Skip to main content

Table 2 Summary of the results for efficacy outcomes based on disease status

From: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma

Outcomes Group HR or RR and 95%CI P value Heterogeneity (%) P value for heterogeneity
OS Previous untreated 0.82 (0.71–0.95) 0.008 29.9 0.180
Relapsed or refractory 0.85 (0.75–0.97) 0.016 0.0 0.471
EFS Previous untreated 0.76 (0.63–0.92) 0.005 72.8 < 0.001
Relapsed or refractory 0.77 (0.58–1.04) 0.084 83.1 < 0.001
ORR Previous untreated 1.00 (0.96–1.05) 0.869 73.5 < 0.001
Relapsed or refractory 1.11 (0.91–1.34) 0.302 65.5 0.013